GlassScriptPhysician profile
Maryellen Walter Rosel
NPI 1821044280
$1,408.64
in general payments reported to CMS, 2019-2025
17 companies · $87.52 in 2025
The $87.52 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $315 · 2021: $293 · 2022: $98.89 · 2023: $163 · 2024: $149 · 2025: $87.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.50 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $185.27 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $169.67 | 2020-2023 | Andexxa |
| E.R. Squibb & Sons, L.L.C. | $151.80 | 2020-2025 | Camzyos, Eliquis |
| Pfizer INC. | $141.74 | 2019-2021 | |
| Novo Nordisk INC | $128.80 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $119.69 | 2019 | |
| Glaxosmithkline, LLC. | $94.84 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $60.28 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $27.37 | 2023 | Teflaro |
| Vertex Pharmaceuticals Incorporated | $25.29 | 2024 | |
| Sanofi-Aventis U.S. LLC | $21.56 | 2019 | |
| Mylan Specialty L.P. | $19.56 | 2020 | |
| Medtronic, INC. | $19.04 | 2023 | Linq II |
| Alexion Pharmaceuticals, INC. | $18.00 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $17.86 | 2025 | Inspire |
| Gilead Sciences, INC. | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryellen Rosel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.